Vildapride D Tablets contain Dapagliflozin 10 mg and Vildagliptin Sustained Release (SR) 100 mg. This fixed-dose combination combines an SGLT2 inhibitor with a DPP-4 inhibitor to provide complementary glycaemic control in adults with Type 2 Diabetes Mellitus.

Vildapride D Tablets offer dual-action glycaemic control by combining Dapagliflozin and Vildagliptin. Dapagliflozin promotes urinary glucose excretion by inhibiting sodium-glucose co-transporter 2 (SGLT2), while Vildagliptin enhances glucose-dependent insulin secretion and suppresses glucagon release by inhibiting dipeptidyl peptidase-4 (DPP-4). This complementary mechanism helps improve fasting and postprandial blood glucose levels with convenient once-daily dosing.

Vildapride D Tablets offer dual-action glycaemic control by combining Dapagliflozin and Vildagliptin. Dapagliflozin promotes urinary glucose excretion by inhibiting sodium-glucose co-transporter 2 (SGLT2), while Vildagliptin enhances glucose-dependent insulin secretion and suppresses glucagon release by inhibiting dipeptidyl peptidase-4 (DPP-4). This complementary mechanism helps improve fasting and postprandial blood glucose levels with convenient once-daily dosing.

Vildapride D Tablets combine two antihyperglycaemic agents with complementary mechanisms of action. Dapagliflozin inhibits sodium-glucose co-transporter 2 (SGLT2), reducing renal glucose reabsorption, lowering the renal threshold for glucose, and increasing urinary glucose excretion. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that rapidly and effectively inhibits DPP-4 activity, increasing endogenous incretin hormone levels. This enhances glucose-dependent insulin secretion from pancreatic beta cells while reducing glucagon secretion, thereby improving overall glycaemic control.

The recommended dosage is one tablet taken orally once daily with food, or as directed by the treating physician.

Vildapride D Tablets are contraindicated in patients with a history of serious hypersensitivity reactions to Dapagliflozin, Vildagliptin, or any component of the formulation, and in patients with metabolic acidosis, including diabetic ketoacidosis.